Form 4: Amicus Therapeutics Executive Jeff Castelli Reports Share Acquisition and Disposal

Chief Development Officer Jeff Castelli reports acquisition of shares through Performance Restricted Stock Units (PRSUs) and disposal of shares to cover tax obligations.

Summary

• Jeff Castelli, Chief Development Officer of Amicus Therapeutics, reported changes in beneficial ownership of company stock on February 11, 2025.
• He acquired 52,338 shares of common stock related to the achievement of 2022 PRSUs, granted by the Board of Directors, at a price of $0.
• Castelli also disposed of 22,724 shares of common stock at a price of $9.57.
• Following these transactions, Castelli directly owns 465,476 shares of Amicus Therapeutics stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reflects routine transactions related to executive compensation. The acquisition of shares through PRSUs is a positive sign, but the disposal is likely for tax purposes.

Positives

• The acquisition of shares reflects the achievement of performance metrics related to the 2022 PRSUs, suggesting positive performance.

Industry Context

Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company executives and directors. This filing indicates activity by a key executive at Amicus Therapeutics.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect routine executive compensation adjustments.

Key Dates

Keywords

Form 4, Beneficial Ownership, Amicus Therapeutics, FOLD, Jeff Castelli, PRSUs, Stock Transaction